Royalty Pharma (RPRX) Profit After Tax Growth (1y) (2020 - 2026)
Royalty Pharma (RPRX) Profit After Tax Growth (1y) (2020 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
PAT Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
66.06% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
17.05% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
-129.68% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-290.15% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-632.44% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Royalty Pharma |
23.13 Bn |
25.57 Bn |
- |
-32.17% |
| Date | Value |
|---|
| Mar 31, 2026 |
-32.17% |
| Dec 31, 2025 |
6.45% |
| Sep 30, 2025 |
-64.26% |
| Jun 30, 2025 |
-51.09% |
| Mar 31, 2025 |
8,992.36% |
| Dec 31, 2024 |
-32.36% |
| Sep 30, 2024 |
1,018.17% |
| Jun 30, 2024 |
-18.58% |
| Mar 31, 2024 |
-98.60% |
| Dec 31, 2023 |
208.39% |
| Sep 30, 2023 |
-49.45% |
| Jun 30, 2023 |
-53.70% |
| Mar 31, 2023 |
166.04% |
| Dec 31, 2022 |
-172.47% |
| Sep 30, 2022 |
39.95% |
| Jun 30, 2022 |
-39.06% |
| Mar 31, 2022 |
-19.43% |
| Dec 31, 2021 |
-41.57% |
| Sep 30, 2021 |
-82.48% |
| Jun 30, 2021 |
836.05% |
